You are here

Home » Content

Ependimomalarda Ki67 Ekspresyonunun Histopatolojik Parametreler ile İlişkisi

Correlation of Ki67 Expression with Histopathological Parameters in Ependymomas

Journal Name:

  • Uludağ Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2011

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
In this study, we aimed to investigate the proliferative activity of ependymomas determined as Ki67 proliferative activity index (PI), and correlate it with parameters such as age, sex, subtype, grade, cellularity, pleomorphism, necrosis or atypic endotelial proliferation. Fifty-eight ependymoma cases diagnosed and operated at Uludağ University from 1997 to 2009 were included in the study. Histologic evaluation was made from the archive prearations which were stained with H-E, GFAP, Ki67 and EMA. There were 38 men (%65.51) and 20 women (%34.49) between the age of 2-72 (mean=33.91±19.50). Although no relation was found between the sex and Ki67 PI; a negative relation was found with age(r=-0.349; p=0.007). Histologically, 3 of the tumors were grade 1 (%5.2), 45 grade 2 (%77.6) and 10 grade 3 (%17.2). A significant relation was found between Ki67 PI and histological grade (r=0.363;p=0.005). While there was a relation between Ki67 PI and cellularity (r=0.289; p=0.028); no significant relation was found with pleomorphism and necrosis (r=0.156, p=0.153). Also there was no relation with endothelial proliferation and the staining patterns of GFAP and EMA with Ki67 PI (p=0.104, p=0.182 ve p=0.567). A significant correlation was found between the grade and cellularity with Ki67 PI.
Bookmark/Search this post with
Abstract (Original Language): 
Çalışmamızın amacı, ependimal tümörlerde Ki67 proliferatif aktivite indeksi (PI)’nin yaş, cinsiyet, tümör grade’i, alt tipleri, sellülarite, pleomorfizm, nekroz, atipik endotel proliferasyonu gibi parametrelerle korelasyonunun belirlenmesidir. Çalışmaya 1997-2009 yılları arasında Uludağ Üniversitesi Tıp Fakültesi’nde opere edilerek ependimoma tanısı almış toplam 58 olgu dahil edildi. Histolojik değerlendirme, H-E ve immunohistokimyasal olarak Ki67, GFAP, EMA ile boyanmış arşiv preparatlarında yapıldı. Olguların 38’i erkek (%65.51), 20’si kadın (%34.49) olup; yaşları 2-72 (ortalama 33.91±19.50) arasında değişmekteydi. Ki67 PI ölçümü ile cinsiyet arasında istatistiksel olarak anlamlı farklılık; Ki67 PI ile yaş arasında negatif korelasyon mevcuttu (r=-0.349; p=0.007). Olguların 3’ü (%5,2) grade 1, 45’i (%77,6) grade 2 ve 10’u (%17,2) grade 3’tü. İstatistiksel olarak Ki67 proliferatif indeksi ile grade arasında anlamlı bir ilişki mevcuttu (r=0,363;p=0,005). Ki67 PI ile sellülarite arasında korelasyon mevcutken (r=0.289; p=0.028); pleomorfizm ve nekroz ile aralarında ilişki saptanmadı (r=0.156, p=0.153). Endotel proliferasyonu, GFAP ve EMA immunohistokimyasal boyalar ile boyanma özellikleri bakımından Ki67 PI ölçümüne göre istatistiksel olarak anlamlı farklılık bulunmadı (p=0.104, p=0.182 ve p=0.567). Sonuç olarak, çalışmamızda grade ve sellülarite ile Ki67 PI arasında istatistiksel olarak korelasyon saptandı.
FULL TEXT (PDF): 
PDF icon arastirmax-ependimomalarda-ki67-ekspresyonunun-histopatolojik-parametreler-ile-iliskisi.pdf
  • 2
93-97
  • Turkish

REFERENCES

References: 

1. Reni M, Gatta G, Mazza E, Vecht C. Ependymoma. Crit. Rev.
Oncol. Hematol. 2007;63 (1):81-9.
2. Wolfsberger S, Fischer I, Höftberger R, et al.Ki67
Immunolabeling Index is an Accurate Predictor of Outcome in
Patients with Intracranial Epenymoma. Am J Surg Pathol.
2004; 28( 7):914-20.
3. McLaughlin MP, Marcus Jr RB, Buatti JM, et al.
Ependymoma: Results, Prognostic Factors and Treatment
Recommendations. Int J Radiat Oncol Biol Phys 1998; 40: 845-
50.
4. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds):
Tumors of the Central Nervous System. Pathology and
Genetics:World Health Organization International
Classification of Tumors. Lyon, IARC Press, 2007, 72-81.
5. Preusser M, Heinzl H, Gelpi E, et al. Ki67 Index in Intracranial
Ependymoma: a Promising Histopathological Candidate
Biomarker. Histopathology 2008; 53(1): 39-47.
6. Burger PC, Scheithauer BW, Vogel FS. Surgical pathology of
the nervous system and its coverings. 4th edition. Philadelphia:
Churchill Livingstone; 2002; 241-54.
7. Suri VS, Tatke M, Singh D, Sharma A. Histological spectrum
of ependymomas and correlation of p53 and ki67 expression
with ependymoma grade and subtype. Ind. J of Cancer.
2004;41(2):66-71.
8. Metellus P, Barrie M, Figarella-Branger D, et al. Multicentric
French study on adult intracranial ependymomas: prognostic
factors analysis and therapeutic considerations from a cohort of
152 patients Brain 2007;130:1338-49.
9. Suzuki S, Oka H, Kawano N, et al. Prognostic value of
Ki67(MIB-1) and p53 in ependymomas.Brain Tumor Pathol
2001; 18:151-4.
10. Vege KD, Giannini C, Scheithauer BW. The immunophenotype
of ependymomas. Appl Immunohistochem Mol Morphol.
2000;8(1):25-31.
11. Guyotat J, Metellus P, Giorgi R, et al. Infratentorial
ependymomas: prognostic factors and outcome analysis in a
multi-center retrospective series of 106 adult patients. Acta
Neurochir 2009; 151:947–60.
12. Korshunov A, Golanov A, Timirgaz V. Immunohistochemical
markers for intracranial ependymoma recurrence: An analysis
of 88 cases.J Neurol Sci. 2000; 1;177(1):72-82.
13. Sharma MC, Ghara N, Jain D,et al. Study of proliferative
markers and tumor suppressor gene proteins in different grades
of ependymomas Neuropathology 2009; 29, 148–55.
14. Kuncova K, Janda A, Kasal P, Zamecnik J.
Immunohistochemical Prognostic Markers in Intracranial
Ependymomas: Systematic Review and Meta-Analysis. Pathol.
Oncol. Res. 2009 ;15:605–14.
15. Metellus P, Figarella-Branger D, Guyotat J,et al. Supratentorial
Ependymomas: Prognostic Factors and Outcome Analysis in a
Retrospective Series of 46 Adult Patients. Cancer.
2008;113(1):175-85.
16. Baradie MM, Elhameed AA, Moneer MM, et al. Ependymoma:
Outcome and Prognostic Factors. Journal of the Egyptian Nat.
Cancer Inst. 2003; 15(1): 73-81.
17. Zulch KJ. Brain tumors: their biology and pathology. 3rd ed.
New York: Springer-Verlag. 1986; 258-76.
18. Goldwein JW, Leahy JM, Packer RJ. Intracranial
ependymomas in children. Int J Radiat Oncol Biol Phys
1990;19:1497-502.
19. Kurt E, Zheng PP, Hop WC, et al. Identification of Relevant
Prognostic Histopathologic Features in 69 Intracranial
Ependymomas, Excluding Myxopapillary Ependymomas and
Subependymomas. Cancer 2006; 15;106(2):388-95.
20. Kawano N, Yagishita S, Hara M, Tadokoro M. Pathologic
features of ependymoma: Histologic patterns and a review of
the literature J Neurooncol. 2001 ;54(1):77-85.
21. Ho DM, Hsu CY, Wong TT, Chiang H. Clinicopathologic
study of 81 patients with ependymomas and proposal of
diagnostic criteria for anaplastic ependymoma. J Neurooncol
2001;54(1):77-85.
22. Kovalic JJ, Flaris N, Grigsby PW, et al.Intracranial
ependymoma long term outcome, patterns of failure. J
Neurooncol 1993;15:125-31.
23. Stuben G, Stuschke M, Kroll M, et al. Postoperative
radiotherapy of spinal and intracranial ependymomas:analysis
of prognostic factors. Radiother Oncol 1997;45:3-10.
24. Ritter AM, Hess KR, McLendon RE, Langford LA.
Ependymomas: MIB-1 proliferation index and survival. J
Neurooncol 1998, 40:51-7.
25. Bennetto L, Foreman N, Harding B, Hayward R, Ironside J,
Love S, Ellison D. Ki67 immunolabeling indeks is a prognostic
indicator in childhood posterior fossa ependymomas.
Neuropathol Appl Neurobiol 1998, 24:434-40.
26. Vanuytsel LJ, Bessell EM, Ashley SE, et al. Intracranial
epenymoma: long-term results of a policy of surgery and
radiotherapy. Int J Radiat Oncol Biol Phys 1992;23:313-9.
27. West CR, Bruce DA, Duffner PK. Ependymomas Factors in
Clinical and Diagnostic Staging. Cancer 1985; 56:1812-16.
28. Massimino M. Ependymoma. Orphanet Encyclopedia. February
2004
29. Humpl T,Neuser H, Brühl K, Bartels U, Schwarz M, Gutjahr P.
Clinical aspects and prognosis of ependymoma in infants and
children. Child’s Nerv Syst 2001; 17:246–51.
30. McGuire CS, Sainani KL, Fisher PG. Both Location and Age
Predict Survival in Ependymoma: A SEER Study. Pediatr
Blood Cancer 2009;52:65–9.

Thank you for copying data from http://www.arastirmax.com